Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 490
- Registration Number
- NCT04704934
- Locations
- 🇦🇷
Instituto Medico Especializado Alexander Fleming, Colegiales, Caba, Argentina
🇦🇷IONC Instituto Oncologico de Cordoba - Fundacion Richardet Longo, Nueva Cordoba, Cordoba, Argentina
🇦🇷Exelsus, San Miguel De Tucumán, Tucumán, Argentina
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04675983
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 3
- Registration Number
- NCT04557384
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Oncology Hematology West, Omaha, Nebraska, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2023-02-10
- Target Recruit Count
- 20
- Registration Number
- NCT04517747
- Locations
- 🇩🇪
Hamburg Hämatologisch-Onkologische Praxis Eppendorf-Facharztzentrum Eppendorf, Hamburg, Germany
🇩🇪Institute for Clinical Cancer Research Krankenhaus Nordwest, Frankfurt, Germany
🇩🇪Tagestherapiezentrum am ITM Universitätsmedizin Mannheim, Mannheim, Germany
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04499924
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
- Conditions
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 31
- Registration Number
- NCT04394624
- Locations
- 🇵🇹
Investigational Site Number : 6200001, Porto, Portugal
🇺🇸Henry Ford Hospital Site Number : 8400005, Detroit, Michigan, United States
🇺🇸Roswell Park Cancer Institute Site Number : 8400003, Buffalo, New York, United States
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- Conditions
- Interventions
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 59
- Registration Number
- NCT04332367
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 117
- Registration Number
- NCT04310007
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸Veterans Administration Medical Center - Birmingham, Birmingham, Alabama, United States
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT04145700
- Locations
- 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's Medical Center Dallas, Dallas, Texas, United States
🇺🇸Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 34
- Registration Number
- NCT04145349
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.